These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 11966706)

  • 1. The transition of pemphigus vulgaris into pemphigus foliaceus: a reflection of changing desmoglein 1 and 3 autoantibody levels in pemphigus vulgaris.
    Harman KE; Gratian MJ; Shirlaw PJ; Bhogal BS; Challacombe SJ; Black MM
    Br J Dermatol; 2002 Apr; 146(4):684-7. PubMed ID: 11966706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile.
    Amagai M; Tsunoda K; Zillikens D; Nagai T; Nishikawa T
    J Am Acad Dermatol; 1999 Feb; 40(2 Pt 1):167-70. PubMed ID: 10025740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels.
    Harman KE; Seed PT; Gratian MJ; Bhogal BS; Challacombe SJ; Black MM
    Br J Dermatol; 2001 Apr; 144(4):775-80. PubMed ID: 11298536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of desmoglein 1 autoantibodies in pemphigus vulgaris: racial differences in frequency and the association with a more severe phenotype.
    Harman KE; Gratian MJ; Bhogal BS; Challacombe SJ; Black MM
    Br J Dermatol; 2000 Aug; 143(2):343-8. PubMed ID: 10951143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical transition between pemphigus foliaceus and pemphigus vulgaris correlates well with the changes in autoantibody profile assessed by an enzyme-linked immunosorbent assay.
    Komai A; Amagai M; Ishii K; Nishikawa T; Chorzelski T; Matsuo I; Hashimoto T
    Br J Dermatol; 2001 Jun; 144(6):1177-82. PubMed ID: 11422038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris.
    Mahoney MG; Wang Z; Rothenberger K; Koch PJ; Amagai M; Stanley JR
    J Clin Invest; 1999 Feb; 103(4):461-8. PubMed ID: 10021453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of pemphigus vulgaris in a patient with pemphigus foliaceus: antidesmoglein antibody profile shift confirmed by enzyme-linked immunosorbent assay.
    Ishii K; Amagai M; Ohata Y; Shimizu H; Hashimoto T; Ohya K; Nishikawa T
    J Am Acad Dermatol; 2000 May; 42(5 Pt 2):859-61. PubMed ID: 10767686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies to the amino-terminal domain of desmoglein 1 are retained during transition from pemphigus vulgaris to pemphigus foliaceus.
    España A; Koga H; Suárez-Fernández R; Ohata C; Ishii N; Irarrazaval I; Teye K; Ohyama B; Hashimoto T
    Eur J Dermatol; 2014; 24(2):174-9. PubMed ID: 24776707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T lymphocytes from a subset of patients with pemphigus vulgaris respond to both desmoglein-3 and desmoglein-1.
    Lin MS; Swartz SJ; Lopez A; Ding X; Fairley JA; Diaz LA
    J Invest Dermatol; 1997 Dec; 109(6):734-7. PubMed ID: 9406813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Desmoglein 1 and 3 Autoantibody Levels in Endemic Pemphigus Foliaceus and Pemphigus Vulgaris from Brazil.
    Oliveira LA; Marquart-Filho A; Trevilato G; Timoteo RP; Mukai M; Roselino AM; Petzl-Erler ML
    Clin Lab; 2016 Jul; 62(7):1209-1216. PubMed ID: 28164651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Detection of serum desmoglein antibody level using enzyme-linked immunosorbent assay (ELISA) for monitoring disease activity in patients with pemphigus vulgaris].
    Zhong S; Qiu YF; Han BB; Zhao JY; Zhu XJ; Chen XX
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Jun; 43(3):414-5. PubMed ID: 21681274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity.
    Daneshpazhooh M; Chams-Davatchi C; Khamesipour A; Mansoori P; Taheri A; Firooz A; Mortazavi H; Esmaili N; Dowlati Y
    J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1319-24. PubMed ID: 17958835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunofluorescence and immunoblot studies on the reactivity of pemphigus vulgaris and pemphigus foliaceus sera with desmoglein 3 and desmoglein 1.
    Hashimoto T; Amagai M; Garrod DR; Nishikawa T
    Epithelial Cell Biol; 1995; 4(2):63-9. PubMed ID: 8688919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with non-pathogenic antibodies against desmoglein-3 in pemphigus foliaceus.
    Vernal S; Julio TA; Alves FH; Turatti A; Donadi EA; Roselino AM
    An Bras Dermatol; 2024; 99(5):680-687. PubMed ID: 38851894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of BIOCHIP technique in diagnosis of different types of pemphigus: Vulgaris and foliaceus.
    Adaszewska A; Kalinska-Bienias A; Jagielski P; Wozniak K; Kowalewski C
    J Immunol Methods; 2019 May; 468():35-39. PubMed ID: 30910537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus.
    Amagai M; Komai A; Hashimoto T; Shirakata Y; Hashimoto K; Yamada T; Kitajima Y; Ohya K; Iwanami H; Nishikawa T
    Br J Dermatol; 1999 Feb; 140(2):351-7. PubMed ID: 10233237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of mucosal involvement in pemphigus foliaceus may be due to low expression of desmoglein 1.
    Shirakata Y; Amagai M; Hanakawa Y; Nishikawa T; Hashimoto K
    J Invest Dermatol; 1998 Jan; 110(1):76-8. PubMed ID: 9424092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E-cadherin autoantibody profile in patients with pemphigus vulgaris.
    Oliveira ME; Culton DA; Prisayanh P; Qaqish BF; Diaz LA
    Br J Dermatol; 2013 Oct; 169(4):812-8. PubMed ID: 23725016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five Japanese cases of antidesmoglein 1 antibody-positive and antidesmoglein 3 antibody-negative pemphigus with oral lesions.
    Koga H; Ohyama B; Tsuruta D; Ishii N; Hamada T; Dainichi T; Natsuaki Y; Sogame R; Fukuda S; Karashima T; Tada J; Yamashiro M; Uezato H; Chan PT; Hashimoto T
    Br J Dermatol; 2012 May; 166(5):976-80. PubMed ID: 22242828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3.
    Cheng SW; Kobayashi M; Kinoshita-Kuroda K; Tanikawa A; Amagai M; Nishikawa T
    Br J Dermatol; 2002 Aug; 147(2):261-5. PubMed ID: 12174096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.